Frankfurt - Delayed Quote EUR

Larimar Therapeutics, Inc. (ZA71.F)

Compare
3.1600
-0.0200
(-0.63%)
As of 8:01:42 AM GMT+1. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Dr. Carole S. Ben-Maimon M.D. CEO, President & Director 841.68k -- 1959
Mr. Michael Celano CPA Secretary & CFO 562.01k -- 1959
Dr. Gopi Shankar M.B.A., Ph.D. Chief Development Officer 577.04k -- 1971
Mr. John Berman Vice President of Finance & Administration -- -- --
Ms. Jennifer Spokes Johansson Vice President of Legal & Compliance -- -- --
Dr. Russell G. Clayton Sr., D.O, D.O. Chief Medical Officer -- -- 1961
Mr. Francis Michael Conway CPA VP & Controller -- -- --

Larimar Therapeutics, Inc.

Three Bala Plaza East
Suite 506
Bala Cynwyd, PA 19004
United States
844 511 9056 https://www.larimartx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
42

Description

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Corporate Governance

Larimar Therapeutics, Inc.’s ISS Governance QualityScore as of January 1, 2025 is 8. The pillar scores are Audit: 6; Board: 7; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

March 12, 2025 at 10:59 AM UTC - March 17, 2025 at 12:00 PM UTC

Larimar Therapeutics, Inc. Earnings Date

Recent Events